S100B and melanoma: We analysed the risk of death and median overall survival for metastatic melanoma patients treated with anti-PD-1 classifying the patients according to demographics, distant metastasis stage and serum S100B and LDH levels at the beginning of therapy, and clinicopathological features of primary melanoma.